Skip to main navigation Skip to search Skip to main content

Targeting the Microcephalin-1 Tumour Suppressor Protein in Cancer

  • Isobel Chapman

Abstract

Microcephalin-1 (MCPH1) is a tumour suppressor protein that is down-regulated in several cancer types and has roles in DNA repair and cell cycle regulation. Specifically, MCPH1 assists homologous recombinant repair (HRR) – a pathway crucial for the repair of DNA double strand breaks (DSBs), with studies suggesting that MCPH1 regulates the recruitment of BRCA2 to the site of damage. HRR-defective cells (e.g. lacking BRCA1/BRCA2) show sensitivity to Poly (ADP-Ribose) Polymerase-1 (PARP) inhibitors (PARPi) via synthetic lethality. Phenotypically, MCPH-1 deficient cells display tightly packed premature chromosome condensation (PCC) before mitosis. This project initially aims to investigate whether MCPH1 deficiency in cancer can be targeted therapeutically through targeting either (i) defective HRR with PARP inhibitors or (ii) sensitivity to classical chemotherapy agents or (iii) PCC phenotype, with tightly packed DNA potentially being resistant to normal DNA repair after classical genotoxic therapeutic agents.
HeLa (cervical carcinoma) and U2OS (osteosarcoma) cells were treated with siRNA against MCPH1 or BRCA2 (positive control for HRR-deficiency and PARPi sensitivity) and knockdown confirmed (~97 %) via Western blotting. Sensitivity of MCPH1-deficient cells to clinically relevant PARPi (AZD-2461 and Talazoparib) was investigated using MTS and colony assays. HRR status was analysed using immunofluorescence used to quantify H2AX foci post Etoposide DSB induction and the Direct-Repeat-GFP (DR-GFP) reporter gene assay was used to investigate HRR proficiency using flow cytometry. Sensitivity of MCPH1 to classical genotoxic chemotherapeutics (Etoposide, Cisplatin and Temozolomide) was also investigated. Fluorescence microscopy was used to identify and quantify the PCC phenotype (a characteristic of MCPH-1 deficient cells). Cells were synchronised in G2-phase of the cell cycle to potentially increase the percentage of MCPH-1 deficient cells displaying the PCC phenotype. FACS analysis was used to determine cell cycle distributions.
MTS and colony data showed little/no sensitivity of MCPH1-deficient cells to either PARPi (compared to control cells), whereas BRCA2-deficient cells showed marked sensitivity. Assessment of HRR-proficiency showed a slight increase in H2AX foci and thus DSBs in MCPH1-deficient cells, whilst BRCA2-deficient cells displayed a substantial increase in DSBs. The DR-GFP assay showed a ~46% decrease in HRR in MCPH1-deficient cells compared to control, while BRCA2-deficient cells showed a more marked (~81%) reduction. MCPH1-deficient cells demonstrated little to no sensitivity to chemotherapeutic agents and BRCA1/2-deficient cells exhibited unexpected inconsistent sensitivity. Images obtained on the microscope show the PCC phenotype associated with MCPH1-deficient cells (SiMCPH1), patchy/punctuate DAPI staining corroborate condensed chromosomes with an intact nuclear membrane. Flow cytometry confirmed an increase in cells arrested in G2. After G2 synchronisation MCPH1-deficient cells enriched in G2 treated with Cisplatin or Temozolomide did not demonstrate marked sensitivity.
Overall, MCPH1-deficient cells did not show significant sensitivity to PARPi or classic chemotherapy agents, regardless of the observed HRR defect. In contrast, BRCA2-deficient cells demonstrated PARPi sensitivity, correlated with marked HRR-deficiency. This suggests that the magnitude of HRR-defect defines the sensitivity to PARP inhibition and DNA-damaging chemotherapeutics.
Date of Award28 May 2026
Original languageEnglish
Awarding Institution
  • Northumbria University
SupervisorPaul Jowsey (Supervisor) & Stephany Veuger (Supervisor)

Keywords

  • DNA Damage
  • PARP Inhibition
  • Homologous Recombinant Repair
  • PCC Phenotype

Cite this

'